Published in Mod Pathol on May 21, 2010
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response. Proc Natl Acad Sci U S A (2015) 1.43
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell (2017) 1.39
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer (2013) 1.32
Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol (2015) 1.24
B7-h3 and its role in antitumor immunity. Clin Dev Immunol (2010) 1.14
Host b7x promotes pulmonary metastasis of breast cancer. J Immunol (2013) 1.05
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. Br J Cancer (2014) 1.03
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med (2011) 1.01
B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol (2012) 0.95
Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep (2014) 0.93
Breast Cancer Detection by B7-H3-Targeted Ultrasound Molecular Imaging. Cancer Res (2015) 0.91
Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection. J Immunol (2012) 0.91
Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients. Ann Surg Oncol (2014) 0.90
Structure and T cell inhibition properties of B7 family member, B7-H3. Structure (2013) 0.90
Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol (2015) 0.89
Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. Clin Cancer Res (2014) 0.89
B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients. Oncol Lett (2014) 0.88
Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. Br J Cancer (2014) 0.88
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer (2014) 0.86
Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer. Oncol Lett (2013) 0.85
Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses. Eur J Immunol (2012) 0.85
MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. Immunol Endocr Metab Agents Med Chem (2012) 0.84
B7-H3 expression in breast cancer and upregulation of VEGF through gene silence. Onco Targets Ther (2014) 0.83
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer. Int J Clin Exp Pathol (2015) 0.81
B7-H3 expression associates with tumor invasion and patient's poor survival in human esophageal cancer. Am J Transl Res (2015) 0.81
Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues. PLoS One (2013) 0.80
B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol (2012) 0.80
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol (2016) 0.79
Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. J Biol Chem (2015) 0.78
Cloning and characterization of porcine 4Ig-B7-H3: a potent inhibitor of porcine T-cell activation. PLoS One (2011) 0.78
Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma. Oncol Lett (2015) 0.77
Upregulation of the B7/CD28 family member B7-H3 in bladder cancer. Oncol Lett (2014) 0.77
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev (2017) 0.77
Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-κB pathway. Sci Rep (2016) 0.77
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Mol Ther Oncolytics (2014) 0.77
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin Cancer Res (2016) 0.76
Control of the adaptive immune response by tumor vasculature. Front Oncol (2014) 0.76
HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res (2016) 0.75
The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Front Immunol (2016) 0.75
Endothelial cells in the eyes of an immunologist. Cancer Immunol Immunother (2012) 0.75
Prognostic biomarkers in ovarian cancer. Cancer Biomark (2011) 0.75
B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol (2017) 0.75
Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer. Int J Mol Sci (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Cancer of the ovary. N Engl J Med (2004) 11.21
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Progress in human tumour immunology and immunotherapy. Nature (2001) 6.97
VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96
The PD-1-PD-L pathway in immunological tolerance. Trends Immunol (2006) 4.52
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
Specialization of tumour vasculature. Nat Rev Cancer (2002) 3.30
B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity (2003) 3.18
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol (2003) 3.18
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Murine B7-H3 is a negative regulator of T cells. J Immunol (2004) 2.33
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol (2008) 2.09
Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol (2008) 2.08
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res (2005) 1.94
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol (2008) 1.90
Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics (2003) 1.81
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res (2009) 1.74
Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer (2005) 1.63
Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol (2006) 1.57
B7-H4 overexpression in ovarian tumors. Gynecol Oncol (2005) 1.51
An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol (2000) 1.41
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer (2009) 1.32
B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol (2007) 1.25
The immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placenta. Am J Pathol (2005) 0.98
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 5.13
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2004) 3.85
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. J Clin Oncol (2014) 3.57
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 3.50
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol (2002) 3.49
Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol (2007) 3.25
Practice patterns in choice of left double-lumen tube size for thoracic surgery. Anesth Analg (2008) 3.25
Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol (2009) 3.11
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol (2011) 2.80
Intrapartum elective cesarean delivery: a previously unrecognized clinical entity. Obstet Gynecol (2004) 2.79
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol (2013) 2.76
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 2.71
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol (2003) 2.67
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
A quantitative measurement of the human somatic mutation rate. Cancer Res (2005) 2.55
Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol (2003) 2.55
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) (2008) 2.47
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol (2009) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol (2008) 2.30
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res (2007) 2.28
Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol (2008) 2.27
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity (2004) 2.21
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res (2002) 2.21
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med (2010) 2.20
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev (2008) 2.08
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials (2008) 2.06
Management of low grade papillary bladder tumors. J Urol (2007) 2.04
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (2008) 1.99
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol (2002) 1.99
Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol (2009) 1.98
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol (2004) 1.97
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res (2006) 1.94
Use of information resources by patients with cancer and their companions. Cancer (2004) 1.93
T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity (2007) 1.92
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91